NASDAQ · NSPR

InspireMD, Inc.

$0.69 +$0.01 (+0.87%) 1D After hours

Key Metrics

$32.02M
Market cap
P/E · TTM
$10.85M
Revenue · TTM
−$51.31M
Net income
EPS · TTM $-1.03
Dividend yield
Free cash flow −$40.15M
Beta · 1Y 0.79
EBITDA · TTM −$50.71M
Gross margin 28.1%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    A material event was filed (Form 8-K).

    8-K - InspireMD, Inc. (0001433607) (Filer)

    RECEIPT: SEC FORM 8-K, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 26
    The stock moved +9.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 26
  • Jun 25
    From its Feb 24 high, the share price fell 65%.

    Peak close $1.85 on Feb 24; trough close $0.66 on Jun 25. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -65%
  • Mar 17
    The stock moved +9.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 17

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$32.02M
Enterprise value
Shares outstanding46.8M
52-wk range$0.63 – $2.93
Avg volume · 20D168.4K
Net cash
Book value / share$0.87
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About InspireMD, Inc.
IPO dateAug 22, 1997
Employees127

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S2.95
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross 28.1%
Operating -472.4%
Net -473.0%
FCF -370.1%
ROE / ROIC -128.8% · —

Financial Health

Current ratio5.15
Quick ratio4.82
Debt / equity
Debt / EBITDA
Net cash
Working capital$39.15M

Cash Flow · TTM

Operating CF −$38.65M
Capex −$1.50M
Free cash flow −$40.15M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-8.3
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings